Activity of Anti-epidermal Growth Factor Receptor Monoclonal Antibody C225 against Glioblastoma Multiforme

This publication has 42 references indexed in Scilit:

• Targeted Toxin Therapy for Malignant Astrocytoma
  Neurosurgery, 2000
• Epidermal Growth Factor Receptor Inhibition in Cancer Therapy: Biology, Rationale and Preliminary Clinical Results
  Investigational New Drugs, 1999
• Iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with recurrent malignant gliomas: phase I trial results.
  Journal of Clinical Oncology, 1998
• The Hydroxyurea-induced Loss of Double-Minute Chromosomes Containing Amplified Epidermal Growth Factor Receptor Genes Reduces the Tumorigenicity and Growth of Human Glioblastoma Multiforme
  Neurosurgery, 1998
• Hydroxyurea Accelerates the Loss of Epidermal Growth Factor? Receptor Genes Amplified As Double-minute Chromosomes in Human Glioblastoma Multiforme
  Neurosurgery, 1996
• Specific targeting of a mutant, activated egf receptor found in glioblastoma using a monoclonal antibody
  International Journal of Cancer, 1995
• Receptor blockade with monoclomal antibodies as anti-cancer therapy
  Pharmacology & Therapeutics, 1994
• Effects of EGF, BFGF, NGF and PDGF(bb) on cell proliferative, migratory and invasive capacities of human brain‐tumour biopsies In Vitro
  International Journal of Cancer, 1993
• Epidermal growth factor stimulates vascular endothelial growth factor production by human malignant glioma cells: a model of glioblastoma multiforme pathophysiology.
  Molecular Biology of the Cell, 1993
• Patient age, histologic features, and length of survival in patients with glioblastoma multiforme
  Cancer, 1987